Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD

Courtney Crim, Mark T Dransfield, Jean Bourbeau, Paul W Jones, Nicola A Hanania, Donald A Mahler, Jørgen Vestbo, Andrew Wachtel, Fernando J Martinez, Frank Barnhart, Sally Lettis, Peter M A Calverley

120 Citationer (Scopus)

Abstrakt

RATIONALE: Radiographically confirmed pneumonia risk with inhaled corticosteroid use in chronic obstructive pulmonary disease (COPD) has not been assessed to date.

OBJECTIVES: To determine the incidence of pneumonia, risk factors, and clinical attributes with inhaled fluticasone furoate (FF) in patients with COPD with an exacerbation history.

METHODS: Two replicate, 1-year, double-blind clinical trials enrolled subjects with COPD with moderate to very severe airflow limitation and at least one exacerbation within the prior year. Subjects were randomized 1:1:1:1 to receive inhaled once-daily vilanterol (VI) 25 μg or VI 25 μg combined with 50, 100, or 200 μg FF. Subjects were required to have a chest radiograph at screening and within 48 hours of any suspected pneumonia or exacerbation.

MEASUREMENTS AND MAIN RESULTS: Among 3,255 randomized subjects, 205 pneumonia events occurred in 181 subjects. Chest imaging was available for 195 (95%) of these events. Chest radiographs were also obtained for 1,793 (70%) of the 2,545 moderate and severe exacerbations. For VI alone and the combination with 50, 100, or 200 μg FF, reported pneumonia incidence was 3, 6, 6, and 7%, respectively. However, for events with compatible parenchymal infiltrates, the respective incidences were 2, 4, 4, and 5%. Factors associated with at least a twofold increase in the risk of pneumonia with FF/VI treatment were being a current smoker, having prior pneumonia, body mass index <25 kg/m(2), and severe airflow limitation.

CONCLUSIONS: Radiographically confirmed pneumonia risk is increased with inhaled FF/VI, although at less than investigator-defined rates. Modifiable pneumonia risk factors should be considered when attempting to optimize COPD management. Clinical trial registered with www.clinicaltrials.gov (NCT01009463 [HZC102871]; NCT01017952 [HZC102970]).

OriginalsprogEngelsk
TidsskriftAnnals of the American Thoracic Society
Vol/bind12
Udgave nummer1
Sider (fra-til)27-34
Antal sider8
DOI
StatusUdgivet - jan. 2015

Fingeraftryk

Dyk ned i forskningsemnerne om 'Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD'. Sammen danner de et unikt fingeraftryk.

Citationsformater